

2018 Oral Mucositis Drug Development- Pipeline Analysis Report

https://marketpublishers.com/r/2B1C7B8EC93EN.html

Date: May 2018

Pages: 0

Price: US\$ 999.00 (Single User License)

ID: 2B1C7B8EC93EN

Abstracts

With an estimated \$2 billion market value, the Oral Mucositis disease pipeline presents strong opportunities for development of treatment options. Absence of preventive or curative treatment for the Oral Mucositis is encouraging investigators in major companies to focus on pipeline. Further, an increasing trend towards grant announcements is being observed in the segment.

The disease occurs primarily as a result of damage to epithelium by chemoradiation.

Over 30 companies and universities are focusing on developing treatment options for Oral Mucositis.

To assist investigators and funding and regulatory organizations, VPA Research has come up with a comprehensive report on Oral Mucositis pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.

Current status, developmental phase, participating companies and entities, recent developments, orphan drug/fast track/other designations, drug class are provided for each Oral Mucositis pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.

In addition to complete details of each product, the report provides key trends in Oral Mucositis pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into



the type of drugs being developed and the stages of development.



Contents

1 TABLE OF CONTENTS

- 1.1 List of Figures
- 1.2 List of Tables

2 ORAL MUCOSITIS PIPELINE ANALYSIS

- 2.1 Disease and Pipeline Overview
- 2.2 Oral Mucositis Pipeline Snapshot
- 2.3 Oral Mucositis Pipeline by Phase
- 2.4 Oral Mucositis Pipeline by Company
- 2.5 Oral Mucositis Pipeline by Mechanism of Action

3 ORAL MUCOSITIS- COMPANY WISE PIPELINE ANALYSIS

ActoGeniX

BIOCND

Clevexel Pharma

Colby Pharmaceutical Company

Daewoong Pharmaceutical

Enzychem Lifesciences Corporation

Galera Therapeutics

Genekey Biotech Chengdu Co Ltd

GlycoMira Therapeutics

Humanetics Corporation

Hyloris Pharmaceuticals

INC Research Australia Pty Ltd

Innovation Pharmaceuticals

Intrexon

Izun Pharmaceuticals Corporation

Monopar Therapeutics

Mundipharma International Ltd

Novartis Pharmaceuticals

Onxeo S.A.

Oragenics

PolyMedix

Santalis Pharmaceuticals



SciClone Pharmaceuticals, Inc.

Servier Canada Inc

Soligenix In

Spectrum Pharmaceuticals

Spherium Biomed S.L.

SRI International

Sunny Pharmtech

Wellstat Therapeutics Corporation

4 ORAL MUCOSITIS R&D PIPELINE SNAPSHOTS

Drug wise Pipeline Details

Therapeutic Candidate Name

Originator

Co-Developer/License Partner

Orphan Drug Designation

Development Phase

Mechanism of Action

Current Status

Ongoing Clinical Trial Details

5 RECENT DEVELOPMENTS IN ORAL MUCOSITIS PIPELINE

6 APPENDIX

- 6.1 About VPA Research
- 6.2 Sources and Research Methodology



List Of Figures

LIST OF FIGURES

Figure 1: Oral	Mucositis	Pipeline	by Phase,	H1-	2018	3
----------------	-----------	----------	-----------	-----	------	---

- Figure 2: Oral Mucositis Pipeline by Companies, H1- 2018
- Figure 3: Company Wise Pipeline Drug Phases, H1- 2018
- Figure 4: Oral Mucositis Pipeline by Mechanism of Action, H1-2018
- Figure 5: Mechanism Wise Pipeline Drug Phases, H1-2018



List Of Tables

LIST OF TABLES

Table 1: Oral Mucositis Pipeline by Phase, H1- 2	201	_	1	Н	hase.	/P	e by	Pipelir	cositis	Mu	Oral	1:	able	-
--	-----	---	---	---	-------	----	------	---------	---------	----	------	----	------	---

- Table 2: Oral Mucositis Pipeline by Companies, H1- 2018
- Table 3: Oral Mucositis Pipeline by Mechanism of Action, H1- 2018
- Table 4: ActoGeniX Oral Mucositis Pipeline, May 2018
- Table 5: BIOCND Oral Mucositis Pipeline, May 2018
- Table 6: Clevexel Pharma Oral Mucositis Pipeline, May 2018
- Table 7: Colby Pharmaceutical Company Oral Mucositis Pipeline, May 2018
- Table 8: Daewoong Pharmaceutical Oral Mucositis Pipeline, May 2018
- Table 9: Enzychem Lifesciences Corporation Oral Mucositis Pipeline, May 2018
- Table 10: Galera Therapeutics Oral Mucositis Pipeline, May 2018
- Table 11: Genekey Biotech Chengdu Co Ltd Oral Mucositis Pipeline, May 2018
- Table 12: GlycoMira Therapeutics Oral Mucositis Pipeline, May 2018
- Table 13: Humanetics Corporation Oral Mucositis Pipeline, May 2018
- Table 14: Hyloris Pharmaceuticals Oral Mucositis Pipeline, May 2018
- Table 15: INC Research Australia Pty Ltd Oral Mucositis Pipeline, May 2018
- Table 16: Innovation Pharmaceuticals Oral Mucositis Pipeline, May 2018
- Table 17: Intrexon Oral Mucositis Pipeline, May 2018
- Table 18: Izun Pharmaceuticals Corporation Oral Mucositis Pipeline, May 2018
- Table 19: Monopar Therapeutics Oral Mucositis Pipeline, May 2018
- Table 20: Mundipharma International Ltd Oral Mucositis Pipeline, May 2018
- Table 21: Novartis Pharmaceuticals Oral Mucositis Pipeline, May 2018
- Table 22: Onxeo S.A. Oral Mucositis Pipeline, May 2018
- Table 23: Oragenics Oral Mucositis Pipeline, May 2018
- Table 24: PolyMedix Oral Mucositis Pipeline, May 2018
- Table 25: Santalis Pharmaceuticals Oral Mucositis Pipeline, May 2018
- Table 26: SciClone Pharmaceuticals, Inc. Oral Mucositis Pipeline, May 2018
- Table 27: Servier Canada Inc Oral Mucositis Pipeline, May 2018
- Table 28: Soligenix In Oral Mucositis Pipeline, May 2018
- Table 29: Spectrum Pharmaceuticals Oral Mucositis Pipeline, May 2018
- Table 30: Spherium Biomed S.L. Oral Mucositis Pipeline, May 2018
- Table 31: SRI International Oral Mucositis Pipeline, May 2018
- Table 32: Sunny Pharmtech Oral Mucositis Pipeline, May 2018
- Table 33: Wellstat Therapeutics Corporation Oral Mucositis Pipeline, May 2018



I would like to order

Product name: 2018 Oral Mucositis Drug Development- Pipeline Analysis Report

Product link: https://marketpublishers.com/r/2B1C7B8EC93EN.html

Price: US\$ 999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/2B1C7B8EC93EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:		
Last name:		
Email:		
Company:		
Address:		
City:		
Zip code:		
Country:		
Tel:		
Fax:		
Your message:		
	**All fields are required	
	Custumer signature	

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970